PMID- 23044303
OWN - NLM
STAT- MEDLINE
DCOM- 20130308
LR  - 20220408
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 125
IP  - 19
DP  - 2012 Oct
TI  - Chemerin and apelin are positively correlated with inflammation in obese type 2 
      diabetic patients.
PG  - 3440-4
AB  - BACKGROUND: As two novel adipocytokines, chemerin and apelin play a key role in 
      the pathological process of insulin resistance (IR), glucose metabolism and 
      obesity, researchers have found that the levels of chemerin and apelin changed 
      significantly in type 2 diabetic patients with obesity, however, the underlying 
      mechanism involved remains unclear. The aim of this study was to investigate 
      whether chemerin and apelin play an important role in the pathophysiologic 
      proceeding of diabetes. METHODS: This study enrolled 81 newly diagnosed obese 
      type 2 diabetes mellitus (T2DM) patients (T2DM group, n = 81). All the patients 
      were randomly assigned to DM1 group treated with metformin (n = 41) and DM2 group 
      treated with pioglitazone (n = 40). After hypoglycemic agents treatment, patients 
      under better blood glucose control were chosen to be given antioxidant treatment. 
      Another 79 subjects without T2DM were recruited as normal control group (NC 
      group), including 40 subjects (NC1 group) with normal body mass index (BMI) and 
      39 obese subjects (NC2 group). Levels of chemerin, apelin, BMI, tumor necrosis 
      factor-alpha (TNF-alpha), homeostasis model assessment of IR (HOMA-IR) and 
      8-isoprotaglandim F2alpha (8-iso-PGF2alpha) were examined at baseline and post-treatment. 
      The relationship between chemerin, apelin and BMI, TNF-alpha, HOMA-IR, 8-iso-PGF2alpha 
      was analyzed. RESULTS: The baseline levels of chemerin, apelin, TNF-alpha, HOMA-IR 
      and 8-iso-PGF2alpha in T2DM group were significantly higher than normal control group 
      (P < 0.001). All indices mentioned above were significantly decreased after 
      treatment (P < 0.05). In T2DM patients treated with pioglitazone, indices 
      mentioned above except for HOMA-IR, were decreased significantly compared with 
      patients treated with metformin (P < 0.05). After antioxidant treatment using 
      lipoic acid, levels of chemerin, apelin, TNF-alpha and 8-iso-PGF2alpha were further 
      significantly decreased (P < 0.05). Correlation analysis showed that the levels 
      of chemerin and apelin correlated positively with BMI, TNF-alpha, HOMA-IR and 
      8-iso-PGF2alpha before and after treatment with hypoglycemic agents (P < 0.01). The 
      levels of chemerin and apelin also had positive correlation with TNF-alpha and 
      8-iso-PGF2alpha after antioxidant treatment (P < 0.05). CONCLUSIONS: The levels of 
      chemerin and apelin in obese T2DM patients are closely related to IR. The 
      increased levels may be a result of compensatory response to IR, and also may be 
      the causative factor of IR. The levels of chemerin and apelin correlate closely 
      with oxidative stress and inflammation. The two adipokines may be inflammatory 
      factors playing important roles in the initiation and development of obese T2DM. 
      Chemerin and apelin are related to the pathophysiology of IR, oxidative stress 
      and inflammation.
FAU - Yu, Shan
AU  - Yu S
AD  - Department of Endocrinology, Qilu Hospital of Shandong University, Jinan, 
      Shandong 250012, China.
FAU - Zhang, Ying
AU  - Zhang Y
FAU - Li, Mei-Zhen
AU  - Li MZ
FAU - Xu, Hua
AU  - Xu H
FAU - Wang, Qian
AU  - Wang Q
FAU - Song, Jun
AU  - Song J
FAU - Lin, Peng
AU  - Lin P
FAU - Zhang, Li
AU  - Zhang L
FAU - Liu, Qian
AU  - Liu Q
FAU - Huang, Qing-Xian
AU  - Huang QX
FAU - Wang, Kun
AU  - Wang K
FAU - Hou, Wei-Kai
AU  - Hou WK
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
RN  - 0 (APLN protein, human)
RN  - 0 (Apelin)
RN  - 0 (Blood Glucose)
RN  - 0 (Chemokines)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Intercellular Signaling Peptides and Proteins)
RN  - 0 (RARRES2 protein, human)
RN  - 0 (Thiazolidinediones)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 27415-26-5 (8-epi-prostaglandin F2alpha)
RN  - 9100L32L2N (Metformin)
RN  - B7IN85G1HY (Dinoprost)
RN  - X4OV71U42S (Pioglitazone)
SB  - IM
MH  - Apelin
MH  - Blood Glucose/metabolism
MH  - Body Mass Index
MH  - Chemokines/*metabolism
MH  - Diabetes Mellitus, Type 2/drug therapy/*immunology/*metabolism
MH  - Dinoprost/analogs & derivatives/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Inflammation/*metabolism
MH  - Intercellular Signaling Peptides and Proteins/*metabolism
MH  - Metformin/therapeutic use
MH  - Pioglitazone
MH  - Thiazolidinediones/therapeutic use
MH  - Tumor Necrosis Factor-alpha/metabolism
EDAT- 2012/10/10 06:00
MHDA- 2013/03/09 06:00
CRDT- 2012/10/10 06:00
PHST- 2012/10/10 06:00 [entrez]
PHST- 2012/10/10 06:00 [pubmed]
PHST- 2013/03/09 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2012 Oct;125(19):3440-4.